Back to Search
Start Over
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine.
- Source :
-
Best practice & research. Clinical endocrinology & metabolism [Best Pract Res Clin Endocrinol Metab] 2024 Jul; Vol. 38 (4), pp. 101906. Date of Electronic Publication: 2024 May 21. - Publication Year :
- 2024
-
Abstract
- Injectable first-generation somatostatin receptor ligands (fg-SRLs) are the standard of care of medical treatment for acromegaly. While fg-SRLs control acromegaly in up to 50 % of patients, they may lead to bothersome injection pain and site reactions. Paltusotine is an investigational, highly selective somatostatin receptor subtype 2 agonist, which is administered orally once a day. To date, phase 2 and 3 clinical trials suggest paltusotine treatment can achieve biochemical and symptom control in acromegaly, with a safety profile comparable to those of the fg-SRLs. Since paltusotine is a once-daily oral drug, it may represent a future treatment option for addressing patient preference or improving quality of life.<br /> (Copyright © 2024 Elsevier Ltd. All rights reserved.)
- Subjects :
- Humans
Receptors, Somatostatin agonists
Acromegaly drug therapy
Subjects
Details
- Language :
- English
- ISSN :
- 1878-1594
- Volume :
- 38
- Issue :
- 4
- Database :
- MEDLINE
- Journal :
- Best practice & research. Clinical endocrinology & metabolism
- Publication Type :
- Academic Journal
- Accession number :
- 38845246
- Full Text :
- https://doi.org/10.1016/j.beem.2024.101906